ArticleThe Journal of international medical research2026
Effects of adrenal ablation on blood pressure and target organ damage in deoxycorticosterone acetate-salt hypertensive rats.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundPrimary aldosteronism is a common and underdiagnosed form of secondary hypertension. However, preclinical investigations of adrenal ablation as a potential therapeutic approach for primary aldosteronism treatment are limited.MethodsA deoxycorticosterone acetate-salt hypertensive rat model was established, and the animals were treated with either unilateral adrenal ablation or oral spironolactone for 12 weeks. Blood pressure was continuously monitored throughout the study period. The key endpoints included blood pressure regulation, circulating hormone levels, and target organ damage.ResultsAdrenal ablation markedly reduced blood pressure in deoxycorticosterone acetate-salt hypertensive rats. During the first 8 weeks of treatment, the antihypertensive effect exerted by adrenal ablation was significantly greater than that achieved using oral spironolactone. After 8 weeks, the blood pressure-lowering effects of both interventions were comparable, although each effect remained significantly lower than that in the untreated controls. Moreover, adrenal ablation was more effective than spironolactone in attenuating the target organ damage associated with deoxycorticosterone acetate-salt hypertension.ConclusionsCompared with oral spironolactone, adrenal ablation significantly lowered blood pressure and more effectively attenuated target organ damage in deoxycorticosterone acetate-salt hypertensive rats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.